Andrea Apolo
安德烈亚·阿波洛
MD
Head, Bladder Cancer Section, Genitourinary Malignancies Branch泌尿生殖系统恶性肿瘤科膀胱癌研究部主任
👥Biography 个人简介
Andrea Apolo leads the NCI bladder cancer clinical research program, conducting groundbreaking trials of immunotherapy agents including avelumab and novel combinations. She has made seminal contributions to understanding predictive biomarkers and treatment sequencing in urothelial carcinoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Avelumab Maintenance Immunotherapy
Led JAVELIN Bladder 100 trial demonstrating avelumab maintenance therapy significantly improved overall survival in advanced urothelial carcinoma after platinum chemotherapy.
Biomarker Research in Bladder Cancer
Identified predictive biomarkers for immunotherapy response in urothelial carcinoma, including FGFR alterations and tumor mutational burden as therapeutic targets.
Representative Works 代表性著作
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine (2020)
JAVELIN Bladder 100 phase III trial establishing avelumab maintenance as a new standard of care.
Cabozantinib as Second-Line Therapy for Metastatic Urothelial Carcinoma
Journal of Clinical Oncology (2016)
Phase II trial demonstrating activity of cabozantinib in platinum-refractory urothelial carcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
Matthew Galsky
Icahn School of Medicine at Mount Sinai
Daniel Petrylak
Yale School of Medicine
Sumanta Pal
City of Hope Comprehensive Cancer Center
关注 安德烈亚·阿波洛 的研究动态
Follow Andrea Apolo's research updates
留下邮箱，当我们发布与 Andrea Apolo（National Cancer Institute, NIH）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment